| Literature DB >> 34340212 |
Manisha H Shah1, Whitney S Goldner2, Al B Benson3, Emily Bergsland4, Lawrence S Blaszkowsky5, Pamela Brock1, Jennifer Chan6, Satya Das7, Paxton V Dickson8, Paul Fanta9, Thomas Giordano10, Thorvardur R Halfdanarson11, Daniel Halperin12, Jin He13, Anthony Heaney14, Martin J Heslin15, Fouad Kandeel16, Arash Kardan17, Sajid A Khan18, Boris W Kuvshinoff19, Christopher Lieu20, Kimberly Miller2, Venu G Pillarisetty21, Diane Reidy22, Sarimar Agosto Salgado23, Shagufta Shaheen24, Heloisa P Soares25, Michael C Soulen26, Jonathan R Strosberg27, Craig R Sussman7, Nikolaos A Trikalinos28, Nataliya A Uboha29, Namrata Vijayvergia30, Terence Wong31, Beth Lynn32, Cindy Hochstetler32.
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.Entities:
Mesh：
Year: 2021 PMID： 34340212 DOI： 10.6004/jnccn.2021.0032
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908